Literature DB >> 10710277

Is presurgical treatment with somatostatin analogs necessary in acromegalic patients?

M Losa1, P Mortini, M Giovanelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10710277     DOI： 10.1007/BF03343662

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  10 in total

1.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

2.  Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate.

Authors:  A L Barkan; R V Lloyd; W F Chandler; M K Hatfield; S S Gebarski; R P Kelch; I Z Beitins
Journal:  J Clin Endocrinol Metab       Date:  1988-11       Impact factor: 5.958

Review 3.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

4.  Presurgical Octreotide: treatment in acromegaly.

Authors:  A Stevenaert; A Beckers
Journal:  Metabolism       Date:  1996-08       Impact factor: 8.694

5.  Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.

Authors:  U Plöckinger; M Reichel; U Fett; W Saeger; H J Quabbe
Journal:  J Clin Endocrinol Metab       Date:  1994-11       Impact factor: 5.958

6.  Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.

Authors:  T Lucas-Morante; J García-Uría; J Estrada; G Saucedo; A Cabello; J Alcañiz; B Barceló
Journal:  J Neurosurg       Date:  1994-07       Impact factor: 5.115

7.  Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations.

Authors:  G A Spinas; J Zapf; A M Landolt; G Stuckmann; E R Froesch
Journal:  Acta Endocrinol (Copenh)       Date:  1987-02

8.  Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly.

Authors:  B Merola; A Cittadini; A Colao; D Ferone; S Fazio; D Sabatini; B Biondi; L Saccá; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1993-09       Impact factor: 5.958

9.  Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).

Authors:  R Fahlbusch; M Giovanelli; M Buchfelder; M Losa
Journal:  J Endocrinol Invest       Date:  1993-06       Impact factor: 4.256

10.  Octreotide treatment of acromegaly. A randomized, multicenter study.

Authors:  S Ezzat; P J Snyder; W F Young; L D Boyajy; C Newman; A Klibanski; M E Molitch; A E Boyd; L Sheeler; D M Cook
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391
  10 in total
  1 in total

1.  Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against.

Authors:  M Losa; V G Crippa
Journal:  J Endocrinol Invest       Date:  2012-06       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.